Alex Mindlin, a Principal, with Valuate Health joins The IDI host Ira Apfel to explain message testing and market access -- why it's important for pharma and how to improve it.

Elisa Remoundos, Senior Vice President and Group Creative Director for Entrée Health, discusses social determinants of health and market access.

Our recent episode about prior authorization was one of our most popular episodes so, to continue the conversation, we invited a payer executive, Dr. Andrew Hertler, on to the podcast get his perspective. Hertler is Chief Medical Officer at Evolent Health. Hertler recently co-authored an op-ed about prior authorization. In it, he touched on gold-carding, a controversial solution to addressing prior authorization challenges.

To better understand payer perceptions of pharmaceutical manufacturers, Valuate conducted its Second Annual Market Access Survey -- and the results are eye-opening. Tony Gibson returns to The IDI to break down all of the results.

Justine Hughes of Archbow Consulting explains why hub implementation is the key to a successful drug launch for pharma and market access. Hughes has led hub implementations for years so she's got some great advice -- and some amazing stories to tell.

2024 is just a month away; what will the new year hold for pharma and market access? Everything is up for grabs -- from the fate of the Inflation Reduction Act to the White House. Al Jackson of Valuate joins the IDI to explain what's a stake.

October is Breast Cancer Awareness Month, so to honor all breast cancer survivors, The IDI is doing something a little different this episode. Instead of our usual discussion of strategies and tactics to improve market access and commercialization, we invited Cora Meese of Entree Health to share her story about her breast cancer diagnosis and recovery journey.

Prior authorizations are a frustrating hurdle for patients who often need immediate treatment – including those in need of prescription drugs. Guests John Hennessy of Valuate and Syam Palakurthy of SamaCare join The IDI to explain the current state of prior authorization – and what’s at stake for pharma and market access.

What role should pharmaceutical manufacturers and market access teams play in exercise and wellness for cancer? Isn’t their cancer-fighting drug enough? Guests John Hennessy of Valuate Health and Sami Mansfield of Cancer Wellness for Life explain why and how pharma and market access should incorporate wellness into cancer care.

Pull-through – the strategy and tactics designed to encourage physicians to prescribe a drug – is one of the biggest challenges pharmaceutical manufacturers and biotech firms face. Jack Timko, Senior Principal, Valuate Health, returns to The IDI to diagnose the pull-through challenges and explain how data analytics can improve pull-through success rates.